The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis.

被引：0
|
作者：
Maetzel, A
Krahn, M
Naglie, G
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2001年 / 44卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1546
引用
收藏
页码：S310 / S310
页数：1
相关论文
共 50 条
  • [1] The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis
    Maetzel, A
    Krahn, M
    Naglie, G
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (03): : 283 - 292
  • [2] Prescription of rofecoxib and celecoxib by physician specialty for patients with osteoarthritis and rheumatoid arthritis.
    Schnitzer, T
    Kong, S
    Mitchell, J
    Mavros, P
    Watson, D
    Pellissier, J
    Straus, W
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S156 - S156
  • [3] The cost-effectiveness of primary therapist model for the management of patients with rheumatoid arthritis.
    Li, LC
    Maetzel, A
    Davis, AM
    Lineker, S
    Bombardier, C
    Coyte, P
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S508 - S509
  • [4] Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis
    Ruchlin, HS
    Elkin, EB
    Paget, SA
    [J]. ARTHRITIS CARE & RESEARCH, 1997, 10 (06) : 413 - 421
  • [5] Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.
    Wong, JB
    Singh, G
    Kavanaugh, A
    [J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S144 - S144
  • [6] Cost-effectiveness of 102-weeks of infliximab for rheumatoid arthritis.
    Wong, JB
    Breedveld, FC
    Smolen, JS
    Kavanaugh, AF
    van Riel, PL
    Hazes, JMW
    Wong, CJ
    Feagan, BG
    van der Heijde, DM
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S311 - S311
  • [7] COST-EFFECTIVENESS ANALYSIS OF CELECOXIB IN THE TREATMENT OF CHRONIC PAIN IN PATIENTS WITH OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS VERSUS THE USE OF ETORICOXIB OR LUMIRACOXIB IN MEXICO
    Vargas-valencia, J. J.
    Orrantia-Gradin, R.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A103 - A103
  • [8] ESTIMATING THE COST-EFFECTIVENESS OF CELECOXIB FOR OSTEOARTHRITIS IN CHINA
    Wang, B.
    Xie, X. P.
    Furnback, W.
    Chen, C., I
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A46 - A46
  • [9] A cost-effectiveness analysis of treatment options for patients with methotrexate (MTX)-naive rheumatoid arthritis.
    Choi, HK
    Seeger, JD
    Kuntz, KM
    [J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S389 - S389
  • [10] Physician specialty and differences in daily consumption of rofecoxib and celecoxib among patients with osteoarthritis and rheumatoid arthritis
    Schnitzer, TJ
    Kong, SX
    Mitchel, JH
    Mavros, P
    Watson, DJ
    Pellissier, JM
    Straus, WL
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S56 - S56
12345